Abstract:Lassa virus (LASV) is responsible for 100,000-300,000 zoonotic infections annually and poses a threat to public health. Development of antibody-based therapeutics or vaccines has been challenging because neutralizing antibodies – even among Lassa hemorrhagic fever survivors – are generally of low titer, and the target of neutralizing antibodies, the trimeric glycoprotein complex (GPC), a type 1-fusion machine with GP1 and GP2 subunits, has been difficult to produce. Here, we use structure-based design to obtain a soluble LASV GPC by engineering an inter-protomer disulfide (R207GCGP1-L326CGP2) and appending the T4-fibritin trimerization domain. We verified the antigenicity of this prefusion-stabilized LASV GPC against a panel of human antibodies and used electron microscopy (EM) to confirm its trimeric association. We panned the prefusion-stabilized LASV GPC against single domain ‘nanobody’ libraries and identified one of camel origin, which we named D5, which bound GPC with 27 nM affinity and neutralized the Josiah strain of LASV with an IC50 of 12 µg/ml when formatted into a bivalent IgG2a context. The cryo-EM structure of a ternary complex of the D5 nanobody, the antigen-binding fragment of human antibody 8.11G, and LASV GPC revealed D5 to recognize a site-of-vulnerability at the trimer apex. The recognized site appeared to be specific to GPC lacking cleavage of between GP1 and GP2 subunits. Collectively, our findings suggest that GPC-cleavage intermediates may be targets for LASV neutralization and define an apex-situated site of vulnerability for vaccine development. Significance Lassa virus (LASV) infection is expanding outside its traditionally endemic areas in West Africa, posing a biothreat to the world. LASV-neutralizing antibodies, moreover, have proven difficult to elicit. To gain insight into requirements for antibody-mediated neutralization of LASV, we developed a prefusion-stabilized LASV glycoprotein trimer (GPC), panned it against phage libraries comprised single-domain antibodies or nanobodies from shark and camel, and identified one, D5, which – when placed into bivalent IgG2a context – could neutralize LASV. Cryo-EM analysis revealed D5 to recognize a cleavage-dependent site-of-vulnerability at the trimer apex. We propose this apex-situated site to be an attractive target for LASV vaccine and therapeutic development.

Assignment of the Lassa virus transmembrane domain in the prefusion and postfusion states in detergent micelles

Functional Characterization of a Lassa Virus Fusion Inhibitors Adaptive Mutant

Identification of Residues in Lassa Virus Glycoprotein Subunit 2 That Are Critical for Protein Function

A Salt Bridge and Disulfide Bond within the Lassa Virus Fusion Domain Are Required for the Initiation of Membrane Fusion

Functional Characterization of a Lassa Virus Fusion Inhibitor Adaptive Mutant

Identification of residues in Lassa virus glycoprotein 1 involved in receptor switch

Deletion of the First Glycosylation Site Promotes Lassa Virus Glycoprotein-Mediated Membrane Fusion

Crystal Structure of Refolding Fusion Core of Lassa Virus GP2 and Design of Lassa Virus Fusion Inhibitors

Acidic Ph-Induced Conformations and LAMP1 Binding of the Lassa Virus Glycoprotein Spike

Roles of the highly conserved amino acids in the globular head and stalk region of the Newcastle disease virus HN protein in the membrane fusion process.

Acidic pH Triggers Lipid Mixing Mediated by Lassa Virus GP

Prefusion-Stabilized Lassa Virus Trimer Identifies Neutralizing Nanobodies and Reveals an Apex-Situated Site of Vulnerability

Construct Design, Biophysical, and Biochemical Characterization of the Fusion Core from Mouse Hepatitis Virus (a Coronavirus) Spike Protein

Effects of N-Linked Glycan on Lassa Virus Envelope Glycoprotein Cleavage, Infectivity, and Immune Response

Lassa virus Z protein hijacks the autophagy machinery for efficient transportation by interrupting CCT2-mediated cytoskeleton network formation

Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability

Conformational ensemble-based framework enables rapid development of Lassa virus vaccine candidates

LaSota Fusion (F) Cleavage Motif-Mediated Fusion Activity is Affected by Other Regions of the F Protein from Different Genotype Newcastle Disease Virus in a Chimeric Virus: Implication for Virulence Attenuation.

Mapping of the Lassa virus LAMP1 binding site reveals unique determinants not shared by other old world arenaviruses

Effects of N-linked glycan of Lassa Virus Envelope Glycoprotein on the Immune Response

Capturing intermediates and membrane remodeling in class III viral fusion